fbpx

molecules of the month

ASTX029

oral ERK1/2 kinase and phosphorylation inhib

Ph. 1/2 candidate for solid tumors

from SBDD from prior lead

Journal of Medicinal Chemistry

Astex Pharmaceuticals, Cambridge, UK

Structure of ASTX029
1 min read

The Astex ERK1/2 kinase inhibitor, ASTX029, is an oral Ph. I-II candidate for patients with advanced solid tumors. The molecule was derived from fragment screening together with structure-based design. Interestingly, the molecule also blocks the phosphorylation/activation of ERK1/2 in addition to inhibiting its kinase activity, making it potentially more effective. Addressing CYP3A4-mediated metabolism while maintaining favorable physicochemical properties was a key aspect of lead optimization. Though metabolism studies highlighted the oxan ring as a key site of metabolism in lead molecule, the sp3-rich moiety was necessary for potency and physicochemical properties. It was found that replacement of a different region of the molecule improved stability, demonstrating that oxan metabolism is context dependent and serving as another example of a molecule having…


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: